Drug Profile
NLA 105
Alternative Names: Genetically modified & expanded haematopoietic stem cell therapy - Nohla TherapeuticsLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Nohla Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Unspecified in USA (Parenteral)
- 24 Oct 2017 Preclinical trials in Undefined indication in USA (Parenteral) before October 2017 (Nohla Therapeutics pipeline, October 2017)